Current Report Filing (8-k)
04 10월 2022 - 6:01AM
Edgar (US Regulatory)
0001444307
false
0001444307
2022-10-01
2022-10-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 1, 2022
ONCOSEC
MEDICAL INCORPORATED
(Exact
Name of Registrant as Specified in Charter)
Nevada |
|
000-54318 |
|
98-0573252 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
24
North Main Street, Pennington, NJ |
|
|
|
08534-2218 |
(Address
of Principal Executive Offices) |
|
|
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (855) 662-6732
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
ONCS |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
October 1, 2022, James M. DeMesa, M.D. notified OncoSec Medical Incorporated (the “Company”) of his resignation from the
Company’s Board of Directors (the “Board”), effective immediately. Concurrently with such resignation, Dr. DeMesa ceased
to serve as Chair of each of the Audit and Nominating and Corporate Governance Committees of the Board and ceased to serve as a member
of the Compensation Committee of the Board. Dr. DeMesa’s resignation from the Board was not the result of any disagreement with
the Company on any matter related to the Company’s operations, policies or practices, or the Company’s management or the
Board.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
October 3, 2022 | OncoSec
Medical Incorporated |
| | |
| By: | /s/
Robert H. Arch |
| Name: | Robert
H. Arch |
| Title: | President
and Chief Executive Officer |
OncoSec Medical (NASDAQ:ONCS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
OncoSec Medical (NASDAQ:ONCS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
OncoSec Medical Incorporated (나스닥)의 실시간 뉴스: 최근 기사 0
More Oncosec Medical Inc News Articles